Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleni Efstathiou

Showing results (121-130 of 150) with videos related to

Pageof 15
Sort By:
Nature Medicine|October 7, 2025
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trialGerhardt Attard, Neeraj Agarwal, Julie N Graff, et al.
The New England Journal of Medicine|June 1, 2026
Perioperative Apalutamide in High-Risk Localized Prostate CancerMary-Ellen Taplin, Martin Gleave, Neal D Shore, et al.
The Lancet. Oncology|November 12, 2013
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trialJohn C Araujo, Géralyn C Trudel, Fred Saad, et al.
Science Translational Medicine|September 5, 2014
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastasesXinhai Wan, Paul G Corn, Jun Yang, et al.
Science Signaling|May 22, 2014
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancerLikun Li, Wenjun Chang, Guang Yang, et al.
JAMA Oncology|April 6, 2023
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical TrialChad Tang, Alexander D Sherry, Cara Haymaker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2020
The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy DevelopmentNallasivam Palanisamy, Jun Yang, Peter D A Shepherd, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2021
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findingsUrsula M Vogl, Tomasz M Beer, Ian D Davis, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2016
Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancerFortunato Ferrara, Daniela I Staquicini, Wouter H P Driessen, et al.
Ebiomedicine|June 21, 2016
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate CancerJeri Kim, John W Davis, Eric A Klein, et al.
Pageof 15

Showing results (121-130 of 150) with videos related to

Sort By:
Pageof 15
Nature Medicine|October 7, 2025
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trialGerhardt Attard, Neeraj Agarwal, Julie N Graff, et al.
The New England Journal of Medicine|June 1, 2026
Perioperative Apalutamide in High-Risk Localized Prostate CancerMary-Ellen Taplin, Martin Gleave, Neal D Shore, et al.
The Lancet. Oncology|November 12, 2013
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trialJohn C Araujo, Géralyn C Trudel, Fred Saad, et al.
Science Translational Medicine|September 5, 2014
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastasesXinhai Wan, Paul G Corn, Jun Yang, et al.
Science Signaling|May 22, 2014
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancerLikun Li, Wenjun Chang, Guang Yang, et al.
JAMA Oncology|April 6, 2023
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical TrialChad Tang, Alexander D Sherry, Cara Haymaker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2020
The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy DevelopmentNallasivam Palanisamy, Jun Yang, Peter D A Shepherd, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2021
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findingsUrsula M Vogl, Tomasz M Beer, Ian D Davis, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2016
Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancerFortunato Ferrara, Daniela I Staquicini, Wouter H P Driessen, et al.
Ebiomedicine|June 21, 2016
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate CancerJeri Kim, John W Davis, Eric A Klein, et al.
Pageof 15